Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06090721 · ClinicalTrials.gov registry record · Phase 3
DMT310-009 Topical in the Treatment of Acne Vulgaris
A Phase 3 study, sponsored by Dermata Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 520
- Enrollment target
NCT06090721: Completed Phase 3 study, sponsored by Dermata Therapeutics.
NCT06090721 is a Phase 3 study that has completed, run by Dermata Therapeutics. The registered enrollment target is 520 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06090721, a Phase 3 study, has completed, sponsored by Dermata Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 520 participants
- Enrollment target
Study Summary
The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris
Primary Outcome
Inflammatory and Noninflammatory
Interventions
- DRUG Placebo
- DRUG DMT310
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520 participants |
| Start Date | 2023-12-08 |
| Est. Completion | 2025-04-30 |
| Phase | Phase 3 |
What the finished NCT06090721 record still lists
NCT06090721 is an interventional study that assigns participants to a tested intervention. The registered 520 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (33% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06090721 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06090721 about?
NCT06090721 is a clinical study titled "DMT310-009 Topical in the Treatment of Acne Vulgaris". The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris
What is the current status of trial NCT06090721?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 520 participants. The study started on 2023-12-08. Estimated completion is 2025-04-30.
What interventions are being tested in trial NCT06090721?
The interventions under investigation include: Placebo (DRUG), DMT310 (DRUG).
Who is sponsoring clinical trial NCT06090721?
This trial is sponsored by Dermata Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06090721's enrollment target sits among peer trials
520 717th of 2000 higher than 1,278 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323581 · 520 participants · NA
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
- NCT04656496 · 520 participants · NA
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
- NCT05445778 · 520 participants · Phase 3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
- NCT05498428 · 520 participants · Phase 2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI